Alpha-adrenoceptor Antagonist Improves Underactive Bladder Associated with Diabetic Cystopathy Via Bladder Blood Flow in Rats

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2017 Aug 25

PMID 28835278

Citations 4

Authors

Saori Yonekubo

Satoshi Tatemichi

Kazuyasu Maruyama

Mamoru Kobayashi

Affiliations

Soon will be listed here.

Abstract

Background: Patients with diabetes experience lower urinary tract symptoms. Cystopathy may evolve into underactive bladder (UAB), depending on the degree and duration of the symptoms. In the present study, we aimed to investigate the effects of silodosin, an alpha-adrenoceptor (AR) antagonist, on UAB in a rat model of diabetes mellitus (DM).

Methods: Female Sprague-Dawley rats (6 weeks old) were administered streptozotocin (STZ) (50 mg/kg, i.v.) to establish a DM model. One week after STZ administration, vehicle or silodosin (0.3 or 1 mg/kg/day) was delivered subcutaneously through an osmotic pump. Nine weeks after STZ administration (8 weeks after drug treatment), a catheter was implanted into the bladder under urethane anesthesia. After the measurement of emptied bladder blood flow (BBF), saline was continuously infused into the bladder and intravesical pressure and micturition volume were measured. In another experiment, the bladder was isolated and nerve markers were quantified.

Results: A cystometrogram showed that bladder capacity (BC), residual volume (RV), and bladder extension (BC/bladder weight) increased by 7.43, 10.47, and 3.59 times, respectively, in vehicle rats in comparison with normal rats. These findings suggested the occurrence of UAB-like symptoms in this model. Silodosin (1 mg/kg/day) inhibited the increase in BC and RV by 49.0% and 46.8%, respectively, and caused a decrease in BBF of approximately 25.5% (when the difference between normal and vehicle was set as 100%) in STZ rats. The nerve marker expression levels tended to be decreased in the bladders of STZ rats and these effects were ameliorated by silodosin.

Conclusions: The STZ rats showed increased bladder extension and RV, symptoms that were suggestive of UAB, and these symptoms were ameliorated by silodosin. These results suggested that the alpha-AR antagonist would be useful for the prevention or treatment of UAB.

Citing Articles

Pathogenesis evidence from human and animal models of detrusor underactivity.

Jhang J, Jiang Y, Hsu Y, Ho H, Kuo H Tzu Chi Med J. 2022; 34(3):287-296.

PMID: 35912048 PMC: 9333099. DOI: 10.4103/tcmj.tcmj_284_20.

Established and emerging treatments for diabetes-associated lower urinary tract dysfunction.

Erdogan B, Liu G, Arioglu-Inan E, Michel M Naunyn Schmiedebergs Arch Pharmacol. 2022; 395(8):887-906.

PMID: 35545721 PMC: 9276575. DOI: 10.1007/s00210-022-02249-9.

Therapeutic effect of integrin-linked kinase gene-modified bone marrow-derived mesenchymal stem cells for streptozotocin-induced diabetic cystopathy in a rat model.

Huang Y, Gao J, Zhou Y, Wu S, Shao Y, Xue H Stem Cell Res Ther. 2020; 11(1):278.

PMID: 32650831 PMC: 7350700. DOI: 10.1186/s13287-020-01795-4.

Grape seed proanthocyanidin extract alleviates urethral dysfunction in diabetic rats through modulating the NO-cGMP pathway.

Zhang B, Zhang Z, Ji H, Shi H, Chen S, Yan D Exp Ther Med. 2018; 15(1):1053-1061.

PMID: 29403553 PMC: 5780740. DOI: 10.3892/etm.2017.5499.

References

Schroder A, Colli E, Maggi M, Andersson K . Effects of a vitamin D(3) analogue in a rat model of bladder outlet obstruction. BJU Int. 2006; 98(3):637-42. DOI: 10.1111/j.1464-410X.2006.06342.x. View

Yamanishi T, Yasuda K, Homma Y, Kawabe K, Morita T . A multicenter placebo-controlled, double-blind trial of urapidil, an alpha-blocker, on neurogenic bladder dysfunction. Eur Urol. 1999; 35(1):45-51. DOI: 10.1159/000019818. View

Goi Y, Tomiyama Y, Nomiya M, Sagawa K, Aikawa K, Yamaguchi O . Effects of silodosin, a selective α1A-adrenoceptor antagonist, on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstruction. J Urol. 2013; 190(3):1116-22. DOI: 10.1016/j.juro.2013.03.110. View

Daneshgari F, Liu G, Imrey P . Time dependent changes in diabetic cystopathy in rats include compensated and decompensated bladder function. J Urol. 2006; 176(1):380-6. DOI: 10.1016/S0022-5347(06)00582-9. View

Tyagi P, Smith P, Kuchel G, de Groat W, Birder L, Chermansky C . Pathophysiology and animal modeling of underactive bladder. Int Urol Nephrol. 2014; 46 Suppl 1:S11-21. PMC: 4469340. DOI: 10.1007/s11255-014-0808-9. View

Kiguchi S, Imamura T, Ichikawa K, Kojima M . Oxcarbazepine antinociception in animals with inflammatory pain or painful diabetic neuropathy. Clin Exp Pharmacol Physiol. 2004; 31(1-2):57-64. DOI: 10.1111/j.1440-1681.2004.03950.x. View

Okutsu H, Matsumoto S, Ohtake A, Suzuki M, Sato S, Sasamata M . Effect of tamsulosin on bladder blood flow and bladder function in a rat model of bladder over distention/emptying induced bladder overactivity. J Urol. 2011; 186(6):2470-7. DOI: 10.1016/j.juro.2011.07.085. View

Mizuseki K, Sakamoto T, Watanabe K, Muguruma K, Ikeya M, Nishiyama A . Generation of neural crest-derived peripheral neurons and floor plate cells from mouse and primate embryonic stem cells. Proc Natl Acad Sci U S A. 2003; 100(10):5828-33. PMC: 156286. DOI: 10.1073/pnas.1037282100. View

Sakakibara R, Hattori T, Uchiyama T, Suenaga T, Takahashi H, Yamanishi T . Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst. 2000; 79(2-3):191-5. DOI: 10.1016/s0165-1838(99)00105-8. View

10.

Chancellor M . The overactive bladder progression to underactive bladder hypothesis. Int Urol Nephrol. 2014; 46 Suppl 1:S23-7. DOI: 10.1007/s11255-014-0778-y. View

11.

Ohtake A, Sato S, Sasamata M, Miyata K . Effects of tamsulosin on resting urethral pressure and arterial blood pressure in anaesthetized female dogs. J Pharm Pharmacol. 2006; 58(3):345-50. DOI: 10.1211/jpp.58.3.0008. View

12.

Akiyama K, Hora M, Tatemichi S, Masuda N, Nakamura S, Yamagishi R . KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther. 1999; 291(1):81-91. View

13.

Miyazato M, Yoshimura N, Chancellor M . The other bladder syndrome: underactive bladder. Rev Urol. 2013; 15(1):11-22. PMC: 3651538. View

14.

Sato S, Hatanaka T, Yuyama H, Ukai M, Noguchi Y, Ohtake A . Tamsulosin potently and selectively antagonizes human recombinant α(1A/1D)-adrenoceptors: slow dissociation from the α(1A)-adrenoceptor may account for selectivity for α(1A)-adrenoceptor over α(1B)-adrenoceptor subtype. Biol Pharm Bull. 2012; 35(1):72-7. DOI: 10.1248/bpb.35.72. View

15.

Andersson K . Bladder underactivity. Eur Urol. 2013; 65(2):399-401. DOI: 10.1016/j.eururo.2013.11.005. View

16.

Bhatia J, Gamad N, Bharti S, Arya D . Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data. World J Diabetes. 2014; 5(3):399-406. PMC: 4058745. DOI: 10.4239/wjd.v5.i3.399. View

17.

Liu G, Li M, Vasanji A, Daneshgari F . Temporal diabetes and diuresis-induced alteration of nerves and vasculature of the urinary bladder in the rat. BJU Int. 2010; 107(12):1988-93. DOI: 10.1111/j.1464-410X.2010.09840.x. View

18.

Zeng J, Xie K, Jiang C, Mo J, Lindstrom S . Bladder mechanoreceptor changes after artificial bladder outlet obstruction in the anesthetized rat. Neurourol Urodyn. 2011; 31(1):178-84. DOI: 10.1002/nau.21219. View

19.

Yagihashi S, Mizukami H, Sugimoto K . Mechanism of diabetic neuropathy: Where are we now and where to go?. J Diabetes Investig. 2014; 2(1):18-32. PMC: 4008011. DOI: 10.1111/j.2040-1124.2010.00070.x. View

20.

Daneshgari F, Huang X, Liu G, Bena J, Saffore L, Powell C . Temporal differences in bladder dysfunction caused by diabetes, diuresis, and treated diabetes in mice. Am J Physiol Regul Integr Comp Physiol. 2006; 290(6):R1728-35. DOI: 10.1152/ajpregu.00654.2005. View